Picture of Acrux logo

ACR — Acrux Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

Momentum

Relative Strength (%)
1m-19.44%
3m-34.73%
6m-39.54%
1yr-55.54%
Volume Change (%)
10d/3m+10.66%
Price vs... (%)
52w High-59.38%
50d MA-21.19%
200d MA-39.03%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-67.17%
Return on Equity-82.09%
Operating Margin-167.2%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Acrux EPS forecast chart

Profile Summary

Acrux Limited is an Australia-based pharmaceutical company. The Company is engaged in the development and commercialization a portfolio of generic topical prescription pharmaceutical products, which uses dermal and transdermal drug delivery technology. The Company’s commercialized products include Lenzetto, Evamist and Testosterone Topical Solution. Its Lenzetto is available in approximately 30 countries across the European Union and other markets in the Middle East and Africa. Its estradiol spray is available for sale in the United States where the product is marketed under the Evamist brand. Its Abbreviated New Drug Application (ANDA) for generic topical testosterone solution, 30mg/1.5mL and the Company sells, markets and distributes agreement in the United States. The Company’s pipeline candidates include Jublia, EMLA and Aczone 7.5% Gel. The Company is developing Jublia for the treatment of fungal infection of the nail. It is developing EMLA for the treatment of topical anesthetic.

Directors

Last Annual
June 30th, 2021
Last Interim
December 31st, 2021
Incorporated
March 19th, 1998
Public Since
September 29th, 2004
No. of Shareholders
5,429
No. of Employees
43
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
283,962,972

ACR Share Price Performance

Upcoming Events for ACR

Full Year 2022 Acrux Ltd Earnings Release

Similar to ACR

Picture of AFT Pharmaceuticals logo

AFT Pharmaceuticals

au flag iconAustralian Stock Exchange - SEATS

Picture of Auscann group logo

Auscann group

au flag iconAustralian Stock Exchange - SEATS

Picture of Biome Australia logo

Biome Australia

au flag iconAustralian Stock Exchange - SEATS

Picture of Botanix Pharmaceuticals logo

Botanix Pharmaceuticals

au flag iconAustralian Stock Exchange - SEATS

Picture of Cann Global logo

Cann Global

au flag iconAustralian Stock Exchange - SEATS

FAQ

Or unlock with your email

Or unlock with your email